Literature DB >> 26961066

Heart failure: SGLT2 inhibitors and heart failure -- clinical implications.

Itamar Raz1, Avivit Cahn1.   

Abstract

The latest findings from the EMPA-REG OUTCOME trial show a 34% reduction in hospitalization for heart failure or cardiovascular death in patients receiving empagliflozin, a sodium/glucose cotransporter 2 (SGLT2) inhibitor, compared with placebo. These outstanding results call for discussion of the clinical implications, and in-depth studies of the mechanisms of action of SGLT2 inhibitors.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26961066     DOI： 10.1038/nrcardio.2016.35

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  9 in total

1.  Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization.

Authors:  Husam M Abdel-Qadir; Jack V Tu; Lingsong Yun; Peter C Austin; Gary E Newton; Douglas S Lee
Journal:  Am Heart J       Date:  2010-08       Impact factor: 4.749

Review 2.  Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.

Authors:  Richard E Gilbert; Henry Krum
Journal:  Lancet       Date:  2015-05-23       Impact factor: 79.321

3.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

4.  Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry.

Authors:  Jaewon Oh; Seok-Min Kang; Namki Hong; Jong-Chan Youn; Seongwoo Han; Eun-Seok Jeon; Myeong-Chan Cho; Jae-Joong Kim; Byung-Su Yoo; Shung Chull Chae; Byung-Hee Oh; Dong-Ju Choi; Myung-Mook Lee; Kyu-Hyung Ryu
Journal:  Int J Cardiol       Date:  2013-08-02       Impact factor: 4.164

5.  Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.

Authors:  B Komoroski; N Vachharajani; D Boulton; D Kornhauser; M Geraldes; L Li; M Pfister
Journal:  Clin Pharmacol Ther       Date:  2009-01-07       Impact factor: 6.875

6.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

7.  Heart failure prevalence, incidence, and mortality in the elderly with diabetes.

Authors:  Alain G Bertoni; W Gregory Hundley; Mark W Massing; Denise E Bonds; Gregory L Burke; David C Goff
Journal:  Diabetes Care       Date:  2004-03       Impact factor: 19.112

8.  Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.

Authors:  H J Lambers Heerspink; D de Zeeuw; L Wie; B Leslie; J List
Journal:  Diabetes Obes Metab       Date:  2013-06-05       Impact factor: 6.577

9.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Authors:  David Fitchett; Bernard Zinman; Christoph Wanner; John M Lachin; Stefan Hantel; Afshin Salsali; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  Eur Heart J       Date:  2016-01-26       Impact factor: 29.983
  9 in total
  9 in total

1.  Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al.

Authors:  Manisha Gupte; Prachi Umbarkar; Hind Lal
Journal:  Cardiovasc Drugs Ther       Date:  2017-06       Impact factor: 3.727

Review 2.  Diuretic Treatment in Heart Failure.

Authors:  David H Ellison; G Michael Felker
Journal:  N Engl J Med       Date:  2017-11-16       Impact factor: 91.245

Review 3.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.

Authors:  Guanghong Jia; Michael A Hill; James R Sowers
Journal:  Circ Res       Date:  2018-02-16       Impact factor: 17.367

Review 4.  Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.

Authors:  Patrycja Puchalska; Peter A Crawford
Journal:  Cell Metab       Date:  2017-02-07       Impact factor: 27.287

Review 5.  SGLT2 Inhibitors: Benefit/Risk Balance.

Authors:  André J Scheen
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

Review 6.  Looking back and thinking forwards - 15 years of cardiology and cardiovascular research.

Authors:  Jonathan M Kalman; Sergio Lavandero; Felix Mahfoud; Matthias Nahrendorf; Magdi H Yacoub; Dong Zhao
Journal:  Nat Rev Cardiol       Date:  2019-09-30       Impact factor: 32.419

7.  Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study.

Authors:  Jens Oellgaard; Peter Gæde; Peter Rossing; Rasmus Rørth; Lars Køber; Hans-Henrik Parving; Oluf Pedersen
Journal:  Diabetologia       Date:  2018-05-30       Impact factor: 10.122

Review 8.  Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review.

Authors:  Simge Acar; Sueda Sanli; Cinar Oztosun; Baris Afsar; Alan A Sag; Masanari Kuwabara; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2021-01-03       Impact factor: 2.370

Review 9.  Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.

Authors:  Tricia Santos Cavaiola; Jeremy Pettus
Journal:  Diabetes Metab Syndr Obes       Date:  2018-04-12       Impact factor: 3.168
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.